Upper Tract Urothelial Carcinoma
Advertisement
Drs. Faltas and Wallis delve into the genomics of UTUC, including the evolution of disease and FGFR inhibition potential.
Drs. Murray and Wallis discuss optimal patient selection, size criteria, and surgical ablation and chemoablation together.
The nomogram outperformed 2 conventional models in predictive accuracy and showed higher benefit in decision curve analysis.
Dr. Li details what his study results suggested about ctDNA’s prognostic implications for survival in patients with UTUC.
The study compared ureteroscopic surgery with radical nephroureterectomy.
Researchers used whole-genome sequencing and a 152-gene panel to study the DNA of patients with high-risk UTUC.
Investigators performed IHC of 4 DNA mismatch repair gene-related proteins (MMRPs) on all UTUC specimens.
In URS and RIRS, pulse shapes were significantly different, with Ho:YAG being used in long-pulse and TFL in short-pulse mode.
The novel nomogram demonstrated perfect performance in discrimination ability and clinical net benefit.
Older patients over 70 years of age need improved care and management of UTUC to improve their outcomes.
Patients who had initiated AC 90 days after RNU were examined to determine a relation between treatment efficacy and timing.
Dr. Surena F. Matin shared valuable insights on lymph node dissection and kidney-sparing management for UTUC.
Dr. Katie S. Murray provided insight into identifying candidates for kidney-sparing management of upper tract disease.
The implications of VH have been thoroughly studied in bladder cancer, but further investigation is needed in UTUC.
Does the OLYMPUS trial have practice-changing potential for patients with low-grade, low-volume UTUC?
Breaking down kidney-sparing management for UTUC, ideal patients, and SOC for endoscopic resection or ureter resection.
Data supporting lymph node dissection at time of surgery for UTUC, as well as the risk factors for individual patients.
Detailing the mitomycin gel adverse events, as well as advice for private practice urologists when offering mitomycin gel.
Ideal candidates for nephron sparing management for upper tract disease, as well as candidates for mitomycin gel.
ICIs for upper tract disease after upfront chemotherapy, along with the emerging role of targeted therapies.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.